FDAapproval83% confidence
FDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (her2) as Enhertu recommended for EU approval in HER2+ metastatic solid tumours.
Regulatory Analysis
By clarifying FDA’s regulatory expectations for new entrants and experienced drug developers alike, FDA is supporting prospective generic drug developers and improving the overall quality of ANDAs submitted to the Agency for approval.
Supporting Context
- Therapeutic area
- Oncology · HER2-positive solid tumours
- Sub-indication
- HER2
Related signal: Enhertu recommended for EU approval in HER2+ metastatic solid tumours
Source
FDA document
View source